Nintedanib Wockhardt Uk

Nintedanib, the active ingredient in Nintedanib Wockhardt Uk, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients.

GNH USA supplies Nintedanib Wockhardt Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic agent used in progressive fibrosing lung disorders. - Idiopathic pulmonary fibrosis: slows decline in forced vital capacity and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves lung function decline and stabilises disease activity. - Other progressive fibrosing interstitial lung diseases: may reduce rate of lung function loss in eligible patients.

Nintedanib may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Diarrhoea: frequent loose stools, often mild to moderate. - Nausea: feeling of stomach upset, may occur early in therapy. - Vomiting: occasional episodes, usually self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Decreased appetite: reduced desire to eat, can affect nutritional intake. - Weight loss: unintended loss of body weight over time.

Serious or Rare Side Effects: - Elevated liver enzymes: significant increase in ALT/AST indicating hepatic stress. - Bleeding events: gastrointestinal or other bleeding, especially when combined with anticoagulants. - Cardiovascular events: hypertension or arterial thrombotic events. - Severe infections: opportunistic infections in immunocompromised patients. - Gastrointestinal perforation: rare but potentially life‑threatening ulceration.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks. - Liver monitoring: check ALT/AST before start and periodically during treatment. - Bleeding risk: evaluate concomitant anticoagulant or antiplatelet use and monitor for signs of hemorrhage. - Cardiovascular assessment: review history of hypertension, ischemic heart disease, and manage accordingly. - Gastrointestinal symptoms: advise patients to report persistent diarrhoea or abdominal pain promptly. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nintedanib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑gp inhibitors (e.g., verapamil, amiodarone): can raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - NSAIDs and aspirin: additive risk of gastrointestinal bleeding. - Diuretics: monitor for dehydration that could exacerbate renal side effects.